OLMA Olema Pharmaceuticals, Inc.
USHealthcareAs of 2026-07-10 16:00
Why OLMA matters now
Olema Pharmaceuticals, Inc. (OLMA) is a US stock in Healthcare. The latest InvestLog snapshot shows $11.91 with -3.01% on the session and $1.04B in market capitalization; recent performance reads 1-month -27.40% and YTD -61.96%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-53.1M, and EPS of $-0.52. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -17.9%.
The latest indexable market news headline is "Olema Pharmaceuticals, Inc. (OLMA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $40.00; recent insider activity includes Raman Prakash filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.03
P/S
0.00
EV/EBITDA
-4.22
DCF Value
$0.49
FCF Yield
-17.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-46.0%
ROA
-34.9%
ROIC
-41.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-53.1M | $-0.52 |
| Q4 2025 | $0.00 | $-46.1M | $-0.51 |
| FY 2025 | $0.00 | $-162.5M | $-1.87 |
| Q3 2025 | $0.00 | $-42.2M | $-0.49 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$41.20
Target (Median)
$40.00
Target Range
$35.00 - $48.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.00
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.